Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.22.2
Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 21, 2022
Jan. 01, 2022
Jul. 22, 2016
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
May 24, 2021
Dec. 04, 2020
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common stock, shares authorized       200,000,000   200,000,000   150,000,000      
Common stock par value (in dollars per share)       $ 0.0001   $ 0.0001   $ 0.0001      
Preferred stock, shares authorized       2,000,000   2,000,000   2,000,000      
Preferred stock, shares issued       250,000   250,000   250,000      
Aggregate value of shares subscribed       $ 28   $ 28   $ 4,329      
Common stock, shares issued       104,511,195   104,511,195   93,582,991      
Common stock, shares issuable       41,652   41,652   2,536,607      
Shares available for future sale       587,542   587,542          
Increase in number of shares of common stock authorized 50,000,000                    
Fortress Biotech, Inc [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Issuance of common shares - Founders Agreement (in shares)   2,536,607       1,133,510          
Percentage of fully diluted equity   2.50% 2.50%     2.50%          
Expenses from related party transaction       $ 300 $ 100 $ 500 $ 300        
Issuance of common shares (in shares)           178,582 452,965        
Shares issued, price per share       $ 1.33 $ 3.50 $ 1.33 $ 3.50        
Common stock, shares issuable       41,652   41,652          
Proceeds from issuance of common shares           $ 5,900          
At the Market Offering [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Agent commission (as a percent)                     3.00%
Issuance of common shares (in shares)           6,800,000 16,200,000        
Shares issued, price per share       $ 0.87 $ 3.94 $ 0.87 $ 3.94        
Proceeds from issuance of common shares           $ 5,900 $ 63,800        
Aggregate fees of stock issuance           100 1,200        
Registration Statements [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Sale of Stock aggregate offering price - Founders Agreement                 $ 200,000 $ 100,000  
Shares available for future issuance - Founders Agreement       $ 8,700   $ 8,700          
Class A Common Shares [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common stock, shares issued       845,385   845,385   845,385      
General and administrative [Member] | Fortress Biotech, Inc [Member]                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Expenses from related party transaction       $ 100 $ 400 $ 900 $ 1,600